# Pizarra — PT-pseudo_4a4fedfc1f51 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4a4fedfc1f51
Task: 1

Encounter: Urology - outpatient on 16 Feb 2025.
Referrer: Dr. M. Jansen (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 56-year-old male
  - PSA: 8.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.368 ng/mL²
  - PSA velocity: 2.14 ng/mL/yr
  - Prior PSA: 6.6 ng/mL
  - Prostate volume: 23.08 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.87014735 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.5 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 23 mL. DRE nodus. csPCa 0.87.

Vitals: weight 78 kg, height 175 cm, BMI 25.5, BP 118/79 mmHg, HR 81 bpm. Smoking: Ex-smoker (22 pack-yr, quit 2009).

Chief complaint: A marked increase in serum prostate-specific antigen levels alongside concerning multiparametric magnetic resonance imaging results prompted this clinical evaluation.

History: Initial screening in late 2022 uncovered an elevated prostate-specific antigen reading, leading to ongoing serial assessments and symptom monitoring. He is a 56-year-old retired civil servant, widowed, and resides independently in a retirement community. Lower urinary tract complaints are negligible, scoring 5 on the IPSS questionnaire, and his regular cycling routine covers roughly 20 kilometres twice each week. Alcohol consumption averages 24 units weekly. He explicitly denies any urinary retention or haematuria. His medical background is otherwise clear, noting no active medications or systemic comorbidities. Past interventions include a surveillance colonoscopy and occasional over-the-counter analgesics for mild knee discomfort. A recent trip to southern France was documented, and he indicated that an Arabic interpreter would facilitate communication during this consultation.

Physical examination: DRE reveals a discrete Nodus within the left peripheral zone, while the remainder of the gland maintains uniform symmetry. General assessment shows no abnormalities; vital parameters are stable, respiratory sounds remain clear bilaterally, and peripheral lymph nodes are non-palpable.

Patient info: retired civil servant; Widowed; Lives in retirement community (independent unit).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 24 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.83 +/- 0.14   (95% CI 0.47-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.14  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.05  (few labelled cases resemble this one)
  - 4.8 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=8.5, age=56.0, psad=0.368, dre_ord=1.0, vol=23.08, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (2.14 ng/mL/yr), the specific details of the mpMRI report (beyond PI-RADS 5), or the full laboratory panel/PSA history trend, which are critical for assessing the rate of change and overall risk trajectory.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy (0.83), but the PI-RADS 5 is high, yet the prior biopsy status is 'None'. The PSA velocity of 2.14 ng/mL/yr suggests rapid progression, which might contradict a benign interpretation suggested by the DRE finding ('Nodus'). The wide error bar ($\pm 0.14$) indicates significant disagreement among the training set, suggesting the current data point is highly ambiguous for the model.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant atypical features or volume changes, it could shift the decision towards or away from biopsy.
  <document> PSA history (trend) -> If the trend is stable or decreasing despite the high PSA, it would argue against immediate biopsy.
  <document> laboratory results -> If the full panel shows other markers (e.g., PSA density context) that modify the PI-RADS 5 interpretation, it could alter the risk assessment.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding prior surveillance or LUTS that influence the urgency of the current evaluation.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_4a4fedfc1f51", "radiology_report": "Report Metadata\nSource: Radiology Unit, Maastricht UMC+\nDate Issued: 2025-02-10\nModality: Multiparametric MRI of the Prostate\nReferred for: PSA elevation to 8.5 ng/mL with a palpable nodule on digital rectal exam.\n\nFINDINGS: Glandular volume registers at 23.08 mL. T2 sequences highlight a circumscribed hypointense focus within the left mid-gland peripheral zone, spanning 12 x 10 x 9 mm. Diffusion-weighted acquisitions show profound restriction with matching low apparent diffusion coefficient values. Dynamic contrast-enhanced phases demonstrate early focal enhancement contrasting against adjacent tissue. Extracapsular spread and seminal vesicle involvement are absent.\n\nIMPRESSION: PI-RADS 5 lesion in the left mid-gland peripheral zone. PSAD 0.368 ng/mL/mL. csPCa predicted probability 0.87014735."}
  
  **psa_trend**
  {"case_id": "PT-pseudo_4a4fedfc1f51", "psa_trend": [{"date": "Sep 2022", "val": 8.1}, {"date": "Dec 2023", "val": 5.6}, {"date": "Feb 2025", "val": 8.5}]}
  
  **lab_results**
  {"case_id": "PT-pseudo_4a4fedfc1f51", "laboratory_results": [{"name": "PSA", "val": "8.5 ng/mL", "date": "03 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.52 ng/mL", "date": "03 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "18%", "date": "03 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.5 g/dL", "date": "03 Jan 2025", "flag": ""}, {"name": "WBC", "val": "5.8 x10^9/L", "date": "03 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "269 x10^9/L", "date": "03 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "80 umol/L", "date": "03 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "03 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "16.1 nmol/L", "date": "03 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "69 U/L", "date": "03 Jan 2025", "flag": ""}, {"name": "LDH", "val": "195 U/L", "date": "03 Jan 2025", "flag": ""}]}
  
  **previous_notes**
  {"case_id": "PT-pseudo_4a4fedfc1f51", "previous_notes": [{"date": "19 Oct 2024", "author": "Dr. M. Jansen (GP)", "text": "21 Jun 2024 - Dr. M. Jansen (GP): A routine clinical review took place following a December 2023 PSA reading of 6.6 ng/mL. The upward clinical trend was addressed alongside a confirmation that his medication regimen has not changed. A follow-up PSA measurement was arranged for early 2025 to track the ongoing progression."}, {"date": "21 Jun 2024", "author": "Dr. M. Jansen (GP)", "text": "19 Oct 2024 - Dr. M. Jansen (GP): A scheduled review focused on recent laboratory values and overall symptom load. Lower urinary tract complaints remain minimal, reflected by an IPSS score of 5, while his preference for cycling twice weekly continues without issue. Weekly alcohol intake averages 24 units, and he maintains independent living arrangements within a retirement community setting."}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the left mid-gland peripheral zone
  PSA velocity of 2.14 ng/mL/yr (calculated from trend data)
  PSA has risen from 5.6 ng/mL (Dec 2023) to 8.5 ng/mL (Feb 2025)
  
  AGAINST sampling this patient now:
  DRE finding: Nodus (Nodus)
  Free PSA is 18% (which is generally favorable, though context is needed)

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which contradicts the benign DRE finding. This leans towards the statistical prior of BIOPSY, suggesting the current data warrants invasive investigation.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk imaging and concerning biochemical data. The PI-RADS 5 lesion in the left mid-gland peripheral zone is a decisive factor, which is further supported by a rising PSA from 5.6 ng/mL to 8.5 ng/mL over two years. Although the DRE finding was a nodus, the high PI-RADS score and PSA velocity strongly outweigh this finding, leading to a clear recommendation for sampling.

Variables that carried weight: age=noted, dre=important, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
